ALLM (Calpain Inhibitor)

Base Information

• Chemical Name: ALLM (Calpain Inhibitor)
• CAS No.: 136632-32-1
• Molecular Formula: C19H35N3O4S1
• Molecular Weight: 401.56
• European Community (EC) Number: 603-969-3
• Wikidata: Q27224942
• Mol file: 136632-32-1.mol

Synonyms:Ac-Leu-Leu-methional;Ac-LLM;acetyl-leucinyl-leucinyl-methional;acetyl-leucyl-leucyl-methional;N-acetyl-L-leucinyl-L-leucinyl-methional

Chemical Property of ALLM (Calpain Inhibitor)

Chemical Property:

• Vapor Pressure: 3.69E-18mmHg at 25°C
• Refractive Index: 1.495
• Boiling Point: 676.5°C at 760 mmHg
• Flash Point: 362.9°C
• PSA: 143.17000
• Density: 1.076g/cm³
• LogP: 2.24440
• Storage Temp.: −20°C
• Solubility.: Soluble in ethanol at 20mg/ml
• XLogP3: 2.2
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 13
• Exact Mass: 401.23482778
• Heavy Atom Count: 27
• Complexity: 497

Purity/Quality:

98%,99%, ^*data from raw suppliers

N-Acetyl-L-leucyl-L-leucyl-L-methional ^*data from reagent suppliers

Safty Information:

• Safety Statements: 22-24/25

MSDS Files:

Useful:

• Canonical SMILES: CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CCSC)C=O)NC(=O)C
• Isomeric SMILES: CC(C)C[C@@H](C(=O)NC(CC(C)C)C(=O)NC(CCSC)C=O)NC(=O)C
• Description: ALLM (136632-32-1) is a cell-permeable, peptide aldehyde inhibitor of calpain (calpain I, Ki?= 120 nM, calpain II, Ki?= 230 nM) and other neutral cysteine proteases. Potent inhibitor of cathepsin L (Ki=0.6 nM) and cathepsin B (Ki=100 nM).1?Weak inhibitor of the chymotrypsin-like activity of the proteasome.2?Cell permeable.
• Uses: ALLM (Calpain Inhibitor) is a cell-permeable, peptide aldehyde inhibitor of calpain I and calpain II. ALLM acts as a very potent inhibitor of cathepsin L and the strongest inhibitor of cathepsin B amongst the peptide aldehydes. This compound inhibits the processing of malaria aspartic hemoglobinases plasmepsins I and II?in vitro. ALLM also inhibits other neutral cysteine proteases, and activation-induced programmed cell death. It restores defective immune responses in HIV+ donors. ALLM blocks nitric oxide production by activated macrophages by interfering with transcription of the inducible nitric oxide synthase gene. ALLM also acts as a weak inhibitor of proteasome.